Abstracting and Indexing

  • CrossRef
  • WorldCat
  • Google Scholar
  • ResearchGate
  • Academic Keys
  • DRJI
  • Microsoft Academic
  • Academia.edu
  • OpenAIRE

Tocilizumab As A Potential Treatment for SARS-CoV2 Pneumonia in Cancer Patients: A Case Report of A Patient with Clinical-Radiological Dissociated Response

Article Information

Irene Moreno MD*, Maro de Miguel MD, PhD, Rafael Álvarez MD, Antonio Cubillo MD, PhD, Emiliano Calvo MD, PhD

HM Sanchinarro Hospital-START Madrid, Madrid, Spain

*Corresponding Author: Irene Moreno MD, HM Sanchinarro Hospital-START Madrid, Madrid, Spain

Received: 05 June 2020; Accepted: 29 June 2020; Published: 01 September 2020

Citation: Irene Moreno, Maro de Miguel, Rafael Álvarez, Antonio Cubillo, Emiliano Calvo. Tocilizumab As A Potential Treatment for SARS-CoV2 Pneumonia in Cancer Patients: A Case Report of A Patient with Clinical-Radiological Dissociated Response. Archives of Clinical and Medical Case Reports 4 (2020): 733-737.

View / Download Pdf Share at Facebook


In December 2019, a novel virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of pneumonia in China. As known, this infection then resulted in a pandemia, being still some territories accross the World suffering from that. Currently, there is no specific treatment or approved vaccine and many clinical trials are investigating potential drugs. Among them, immunomodulators seems a group of drugs that could be useful in the Coronavirus-19 disease (Covid-19). Specially, in those cases where a cytokine storm occurs. This involves a considerable release of proinflammatory cytokine including several interleukins and tumour necrosis factor α (TNF-α) . Here, we report the successful treatment of a metastatic colorectal cancer patient hospitalized due to SARS-CoV-2 pneumonia with tocilizumab, an humanized monoclonal antibody against the interleukin-6 receptor (IL-6R).


Acute respiratory syndrome; SARS-CoV-2; Immunomodulators; Tocilizumab

Acute respiratory syndrome articles, SARS-CoV-2 articles, Immunomodulators articles, Tocilizumab articles

Article Details

1. Case Report

Human-affecting coronaviruses (HCoV) can produce clinical symptoms ranging from the common cold to more serious ones such as those caused by the Severe Acute Respiratory Syndrome (SARS) viruses and Middle East Respiratory Syndrome (MERS-CoV). Covid-19 is the term that encompassed the various clinical manifestations

(included SARS-COV2 pneumonia) caused by the emerging virus SARS-CoV-2 [1].

We report the successful treatment of a cancer patient hospitalized due to SARS-CoV-2 pneumonia with tocilizumab. Tocilizumab     [2] is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R), mainly used for the treatment of rheumatoid arthritis and cytokine-release syndrome.Higher plasma levels of cytokines found in ICU patients in China         [2] demonstrated that in the pathogenesis of SARS-CoV-2 pneumonia, a cytokine storm occurred, involving a considerable release of proinflammatory cytokine (including IL-6).

We present the case of a 64 year old gentleman with a history of well-controlled hypertension and KRAS-wildtype metastatic colorectal cancer. His last CT scan done as a F/U for his CRC showed no lung abnormalities with low volumen tumoral disease in partial response - just lymph node involvement on his inguinal area. Patient was at the time receiving treatment inhibiting LAG3 and PDL, being in response for almost a year. He presented to the emergency department (ED) with myalgia, anosmia, dyspnoea and temperature of more than 102,2 °F (39ºC) for 4 days. The physical examination was normal, except for tachycardia (as patient was febrile) and right basal rhonchi. Basal oxygen saturation was 88%. Lymphocites count was 0.47 × 10e3/μL (1.2 - 3.4 × 10e3/μL), D -Dimer was 643,0 ng/mL (< 500 ng/mL), C-reactive protein (CRP) was 409,64 mg/L (< 5 mg/L) (Figure 1).

Procalcitonine levels were low. Arterial Blood Gas (ABG) was: pH 7,47 (7.35 - 7.45), pCO2 32,0 mmHg (35.0 - 45.0) and pO2 53,0 mmHg (75.0 - 100.0). Chest x-ray showed a right basal infiltration. The initial diagnosis was an infectious pneumonia (possibly Covid-19 as per epidemiological situation). Because there was not seen the typical pattern on x-ray for Covid infection and patient had an active cancer being at risk of bacterial/fungal infections, antibiotics/antifungal treatment was also given (with EKG monitorization). A nasopharyngeal (NP) sample was taken for Covid-19 testing coming back as positive in the following day. Patient was started, following the hospital protocol, on colchicine, montelukast, hydroxychloroquine, lopinavir/ritonavir, azithromycin, meropenem, oseltamivir, fluconazole and linezolid. From day 2 to 3 patient had a rapid clinical worsening despite the treatment implemented with maintained high fever and need for oxygen supply with reservoir mask at 15 lpm. This clinical impairment was accompained by a radiological one (with consolidations involving all lobes on the chest film). CRP was up to almost 600 mg/L, lymphocytes went slightly down and D-D was also increased. Ferritine was elevated, as well as IL6 levels 118,3 pg/mL (<7). As blood cultures/legionella-pneumococco urinary antigent tests came back as negative and the Covid infection was confirmed, it was decided to take off antitibiotics/antifungal therapy and a high dose bolus of steroids was given (250 mg methylperdnisolone) on day 3. Later, on day 4, and despite steroids, patient had no improvement of his shortness of breath and oxygen saturation was again worsened (91-92% with 15 lpm reservoir mask). At this point it was decided to infuse him a single dose of 400 mg tocilizumab on the ward. From day 5 to day 8, patient improved rapidly with less dypsnoea since the following day of the tocilizumab infusion. Inflamatory markers were also better (including IL6 levels, RCP, Lymphocytes count and DD). There was first an impaitment on lung xray lesions after the tocilizumab infusion but followed with a reduction in the consolidative lesions in the next days. This clinical-radiological dissociation in COVID-19 has been previously described [4] (Figure 2). For instance, several previous reports described asymptomatic cases who had evidence of lung opacities on chest CT [5, 6].


Figure 1: Clinical/laboratory parameters over hospitalization time.


Figure 2: Chest xraybefore (day 4) and after (day 6 and 8) tocilizumab infusion.

On day 10 patient was not requiring any supplemental oxygen and a new NP sample was taken again for Covid19 being this negative. Patient was finally discharged home on day 12, with no medications. Outcomes from twenty-one patients treated with tocilizumab after being diagnosed of SARS-Cov2 pneumonia were reported in a retrospective clinical study from China [5]. It was shared a significant improvement on symptoms in a relevant number of patients (19/21 patients), oxygen intake and radiological/laboratorios features; with no obvious adverse reactions.

This clinical case shows how anti-IL6 therapy, as tocilizumab, may be effective for patients with severe SARS-COV2 pneumonia. This could be specially useful in patients who have no options for intensive therapies (such as mecanical ventilation or ICU treatments). In these patients, a prompt use of tocilizumab may reduce hospitalization times and fatal outcomes.

Furthermore, this case could be considered as another example of clinical-radiological dissociation in COVID-19. To the best of our knowledge, this discrepancy have not been reported in either MERS-CoV or SARS-Cov infection. Several hypotheses could explain this disparity. One possibility is that there would be a mismatch between the timing of CT/Xray positivity and clinical symptoms like in other types of pneumonia. Positive results in terms of symptoms, time of hospitalization and recovery derived from our patient experience are encouraging for the use of anti-interleukin therapy. However, there are several shortcomings on the assumptions derived from this single case report. Randomized and prospective trials with a higher number of patients are needed [6].

Conflicts of Interest

The authors declare no conflicts of interest.


  1. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. Int J Biol Sci 16 (2020): 1678-1685.
  2. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs 77 (2017): 1865-1879.
  3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020): 497-506.
  4. Chest CT Findings in Cases from the Cruise Ship “Diamond Princess” with Coronavirus Disease 2019 (COVID-19). Radiology: Cardiothoracic imaging (2020).
  5. Ng M-Y, Lee EY, Yang J, et al. Imaging profile of the COVID-19 infection: radiologic findings and literature review. Radiology: Cardiothoracic Imaging 2 (2020): e200034.
  6. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases (2020): 30086.
  7. Xu X, Han M, Li T, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. ChinaXiv:202003.00026v1.
  8. Mahase E. Covid-19: what treatments are being investigated? BMJ 368 (2020): 1252.

Grant Support Articles

    Editor In Chief

    Yasuo Iwasaki

  • Division of Neurology, Department of Internal Medicine
    Toho University School of Medicine
    Ota-ku, Tokyo, Japan

© 2016-2023, Copyrights Fortune Journals. All Rights Reserved!